Scopus BioPharma Inc. SCPS
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -74.56% | -61.47% | -28.37% | 108.45% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.87% | -66.69% | -57.61% | -24.88% | -- |
| Operating Income | 45.87% | 66.69% | 57.61% | 24.88% | -- |
| Income Before Tax | 41.24% | 65.49% | 56.54% | 23.68% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 41.24% | 65.49% | 56.54% | 23.68% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.31% | 66.68% | 56.93% | 23.68% | -- |
| EBIT | 45.87% | 66.69% | 57.61% | 24.88% | -- |
| EBITDA | 45.87% | 66.69% | 57.61% | 24.89% | -- |
| EPS Basic | 60.02% | 74.44% | 65.72% | 40.07% | -- |
| Normalized Basic EPS | 61.55% | 74.90% | 65.90% | 40.06% | -- |
| EPS Diluted | 60.02% | 74.44% | 65.72% | 40.07% | -- |
| Normalized Diluted EPS | 61.55% | 74.90% | 65.90% | 40.06% | -- |
| Average Basic Shares Outstanding | 42.71% | 26.92% | 24.02% | 31.66% | -- |
| Average Diluted Shares Outstanding | 42.71% | 26.92% | 24.02% | 31.66% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |